share_log

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $40

Benzinga Real-time News ·  Nov 8, 2022 11:32

Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $22 to $40.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment